Kidney Research UK

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Retrieved on: 
Wednesday, September 14, 2022

The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.

Key Points: 
  • The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.
  • The trial is a Phase 2, randomized, multicenter, double-blind, parallel-group trial in subjects with CKD-aP stages 3-5.
  • Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.
  • For additional information on MC2 Therapeutics Group, pleasevisit www.mc2therapeutics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/mc2-therapeutics-announces-init...

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Retrieved on: 
Wednesday, September 14, 2022

MC2-25 Cream is an innovative new drug candidate, addressing MC2's new biological treatment paradigm for treatment of urea associated skin diseases.

Key Points: 
  • MC2-25 Cream is an innovative new drug candidate, addressing MC2's new biological treatment paradigm for treatment of urea associated skin diseases.
  • The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.
  • The trial is a Phase 2, randomized, multicenter, double-blind, parallel-group trial in subjects with CKD-aP stages 3-5.
  • Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Monday, September 12, 2022

Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.

Key Points: 
  • Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.
  • It is fantastic to see that the SMC has followed the direction of England and Wales to offer certain highly sensitized patients the opportunity of a life-altering transplant.
  • "We are thrilled that the SMC has recommended Idefirixas the first licensed therapy for highly sensitized kidney patients in Scotland.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Thursday, June 16, 2022

The recommendation marks an important milestone for patients in England, Wales and Northern Ireland, as appropriate specialized transplant centres will be able to use Idefirixto enable transplantation for highly sensitized patients, currently highly unlikely to receive a lifesaving compatible kidney transplant.

Key Points: 
  • The recommendation marks an important milestone for patients in England, Wales and Northern Ireland, as appropriate specialized transplant centres will be able to use Idefirixto enable transplantation for highly sensitized patients, currently highly unlikely to receive a lifesaving compatible kidney transplant.
  • "We welcome this decision, which will allow new opportunities for certain highly sensitized patients to qualify for a life-altering transplant, and gain freedom from dialysis.
  • Decision making around who has access to the treatment is key, and the lifespan of the transplanted kidneys will need to be carefully monitored."
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Statement on Patient Access to New Drug Treatment Options

Retrieved on: 
Wednesday, August 4, 2021

Three entirely new classes of drugs now exist that can modify the progression of kidney disease.

Key Points: 
  • Three entirely new classes of drugs now exist that can modify the progression of kidney disease.
  • In simple terms, more interventions are available than ever before that can keep people with kidney disease alive and untethered to a dialysis machine.
  • Heart disease is the most common cause of death for people with kidney disease.
  • It is more common for people with kidney disease to die of heart disease than it is for them to progress to kidney failure.

Cricket Health StageSmart™ and MyCricket™ Platforms Achieve Hospital Admission Reductions, High Engagement in First Year of Deployment

Retrieved on: 
Wednesday, April 14, 2021

"Our goal at Cricket Health is to give people with kidney disease the support they need to live their best lives.

Key Points: 
  • "Our goal at Cricket Health is to give people with kidney disease the support they need to live their best lives.
  • The frequent engagement we\'re seeing in the MyCricket platform is making a real difference.
  • "\nMyCricket connects people with kidney disease with peer support, a peer mentor, a multidisciplinary care team, and educational resources available 24/7.
  • Using StageSmart, Cricket Health\'s machine learning disease identification model, and predictive GFR (pGFR), Cricket Health helps health plans and providers identify people with kidney disease, determine disease stage, and assess their risk of disease progression.

Somatus Continues to Advance Kidney Care Model with Addition of Senior Scientific Advisor

Retrieved on: 
Tuesday, December 22, 2020

Somatus, the market leader in value-based kidney care, today announced that Dr. Nwamaka Eneanya has joined the Company as Senior Scientific Advisor.

Key Points: 
  • Somatus, the market leader in value-based kidney care, today announced that Dr. Nwamaka Eneanya has joined the Company as Senior Scientific Advisor.
  • Dr. Eneanya will guide clinical research studies to advance the Companys evidence-based approach to care delivery for patients with or at-risk of developing kidney disease.
  • With her guidance and expertise, we can accelerate the impact of the Somatus care model using evidence-based research to improve the quality and experience of care for patients with kidney disease in the communities we serve.
  • I am honored to join the team revolutionizing the kidney care industry and look forward to helping Somatus use research and data to advance their model and mission.

Nationwide Kidney Risk Campaign Relaunches by National Kidney Foundation, U.S. Department of Health and Human Services, and American Society of Nephrology

Retrieved on: 
Tuesday, September 1, 2020

Black or African American and Hispanic or Latino people are also at greater risk of developing kidney disease.

Key Points: 
  • Black or African American and Hispanic or Latino people are also at greater risk of developing kidney disease.
  • "We believe it's essential to reach the more than 80 million American adults at risk for kidney disease, especially communities of color which are at higher risk.
  • campaign, co-sponsored by the National Kidney Foundation, HHS and ASN is part of a new Public Awareness Initiative of the Advancing American Kidney Health (AAKH) plan.
  • campaign will raise awareness of the risk of kidney disease and help millions of Americans take steps to improve their kidney health and prevent the costly, deadly health challenge of kidney disease."

HHS Secretary Azar on Transforming Kidney Care

Retrieved on: 
Thursday, February 28, 2019

The Kidney Patient Summit , led by the National Kidney Foundation , brings together advocates from across the country representing several kidney patient groups, to meet with lawmakers on Capitol Hill to push for early detection, living organ donation, and more funding to fight kidney disease.

Key Points: 
  • The Kidney Patient Summit , led by the National Kidney Foundation , brings together advocates from across the country representing several kidney patient groups, to meet with lawmakers on Capitol Hill to push for early detection, living organ donation, and more funding to fight kidney disease.
  • In the United States 30 million adults are estimated to have chronic kidney disease and most aren't aware of it.
  • 1 in 3 American adults are at risk for chronic kidney disease.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease.

A Path Forward for Increasing Kidney Transplantation

Retrieved on: 
Friday, January 11, 2019

Nearly 680,000Americans have irreversible kidney failure, or end-stage renal disease (ESRD) , and need dialysis or a kidney transplant.

Key Points: 
  • Nearly 680,000Americans have irreversible kidney failure, or end-stage renal disease (ESRD) , and need dialysis or a kidney transplant.
  • These priorities will create a strategic and effective path forward towards increasing the number of kidney transplants and decreasing the number of patients who die waiting.
  • Support community-based programs, like the National Kidney Foundation's THE BIG ASK: THE BIG GIVE , that seek to educate kidney patients and potential kidney donors on the benefits and risks of living donation.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease.